Acrivon Therapeutics, Inc. ACRV

Company Overview

Acrivon Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on precision oncology. The company develops targeted cancer therapies using proteomics-based patient selection technologies intended to identify patients most likely to respond to specific treatments. Acrivon operates within the biotechnology and oncology therapeutics industries, with its strategy centered on combining drug development with predictive biomarker platforms to improve clinical outcomes and reduce inefficiencies associated with broad, non-targeted cancer treatment approaches.

The company’s primary revenue and value drivers are its oncology drug candidates and its proprietary Acrivon Predictive Precision Proteomics (AP3) platform. Its lead clinical programs have included ACR-368, a selective checkpoint kinase inhibitor being evaluated in multiple solid tumors, and additional internally developed oncology candidates focused on DNA damage response and cell-cycle regulation pathways. Acrivon primarily serves oncology patients, clinical research institutions, and the broader precision medicine market. The company was founded to advance a data-driven approach to oncology drug development and has evolved through acquisitions, licensing arrangements, and platform expansion aimed at integrating biomarker discovery with therapeutic development.